Heart drug mavacamten under real-world safety watch in japan
NCT ID NCT07383025
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study monitors the real-world safety and effectiveness of mavacamten in about 200 people in Japan who have obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Participants will be followed to track any side effects and how well the drug works in everyday medical practice. The goal is to ensure the medicine is safe and effective outside of controlled clinical trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
CMIC Co., Ltd
RECRUITINGTokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New heart drug aficamten challenges standard Beta-Blocker in major trial
- Heart drug mavacamten under the microscope: Real-World study launches
- Heart drug mavacamten shows promise in Real-World study
- Gene test may personalize heart drug dosing
- New pill aims to help heart patients breathe easier and move more
- Could a common supplement help hearts pump better?